Frank Torti

Frank Torti serves as Vant Chair at Roivant Sciences and is responsible for the operating companies in the Roivant Pharma family. He previously served as Vant Investment Chair, where he oversaw a group of companies responsible for the development of thirty-five investigational drugs in eleven therapeutic areas and over fifty clinical trials, including four successful Phase 3 trials. Dr. Torti joined Roivant in 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics.

Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. from Harvard Business School.